AU2001297844A1 - Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers - Google Patents

Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers

Info

Publication number
AU2001297844A1
AU2001297844A1 AU2001297844A AU2001297844A AU2001297844A1 AU 2001297844 A1 AU2001297844 A1 AU 2001297844A1 AU 2001297844 A AU2001297844 A AU 2001297844A AU 2001297844 A AU2001297844 A AU 2001297844A AU 2001297844 A1 AU2001297844 A1 AU 2001297844A1
Authority
AU
Australia
Prior art keywords
drug
vinyl pyrrolidone
acetate
vimyl
copolymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001297844A
Other languages
English (en)
Inventor
Henry William Bosch
Niels P. Ryde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Pharma International DAC
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Publication of AU2001297844A1 publication Critical patent/AU2001297844A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AU2001297844A 2000-11-20 2001-11-16 Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers Abandoned AU2001297844A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71511700A 2000-11-20 2000-11-20
US09/715,117 2000-11-20
PCT/US2001/043111 WO2002094215A2 (en) 2000-11-20 2001-11-16 Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers

Publications (1)

Publication Number Publication Date
AU2001297844A1 true AU2001297844A1 (en) 2002-12-03

Family

ID=24872726

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001297844A Abandoned AU2001297844A1 (en) 2000-11-20 2001-11-16 Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers

Country Status (8)

Country Link
EP (1) EP1341521B1 (cg-RX-API-DMAC10.html)
JP (2) JP4541647B2 (cg-RX-API-DMAC10.html)
AT (1) ATE419834T1 (cg-RX-API-DMAC10.html)
AU (1) AU2001297844A1 (cg-RX-API-DMAC10.html)
CA (1) CA2428785C (cg-RX-API-DMAC10.html)
DE (1) DE60137362D1 (cg-RX-API-DMAC10.html)
ES (1) ES2317874T3 (cg-RX-API-DMAC10.html)
WO (1) WO2002094215A2 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
CA2858733C (en) * 2004-12-31 2017-12-19 Iceutica Pty Ltd Nanoparticle compositions and methods for synthesis thereof
CN101287451A (zh) * 2005-05-23 2008-10-15 依兰药物国际有限公司 包含血小板聚集抑制剂的毫微粒和控制释放组合物
WO2007046632A1 (en) * 2005-10-18 2007-04-26 Amorepacific Corporation Cationic polymer nanoparticles encapsulating an active ingredients, and the cosmetic composition containing the same
WO2008002485A2 (en) * 2006-06-23 2008-01-03 Alza Corporation Increased amorphous stability of poorly water soluble drugs by nanosizing
AU2016203251B2 (en) * 2006-06-30 2017-11-16 Iceutica Pty Ltd Methods for the Preparation of Biologically Active Compounds in Nanoparticle Form
JP5508003B2 (ja) * 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
CA2759109A1 (en) 2009-04-24 2010-10-28 Iceutica Pty Ltd A solid dosage form of ciprofloxacin having small particle size and improved powder handling characteristics
NZ710384A (en) 2009-04-24 2017-03-31 Iceutica Pty Ltd A novel formulation of indomethacin
PE20140166A1 (es) * 2010-10-01 2014-02-17 Cipla Ltd Composicion farmaceutica que comprende deferasirox
JP2014129317A (ja) * 2012-02-23 2014-07-10 Canon Inc 光音響造影剤用色素含有ナノ粒子
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
WO2016134121A1 (en) 2015-02-20 2016-08-25 Cytec Industries Inc. Dialkyl sulfosuccinate compositions, method of making, and method of use
AU2017236423A1 (en) * 2016-03-24 2018-11-15 Locate Bio Limited Scaffolding material, methods and uses
GB201810925D0 (en) * 2018-07-03 2018-08-15 Blueberry Therapeutics Ltd Compositions and methods of treatment
ES2984690T3 (es) 2020-06-26 2024-10-30 Algiax Pharmaceuticals Gmbh Composición de nanopartículas
CR20230376A (es) * 2021-01-11 2023-12-12 Bayer Healthcare Llc Formulaciones de gel líquido concentradas que contienen sales de naproxeno

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
ES2188883T3 (es) * 1996-07-08 2003-07-01 Ciba Sc Holding Ag Derivados de triazina como filtro uv en productos antisolares.
RU2186562C2 (ru) * 1996-08-22 2002-08-10 Ресеч Трайангл Фармасьютикалс Лтд. Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
AU6283299A (en) * 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate

Also Published As

Publication number Publication date
ES2317874T3 (es) 2009-05-01
WO2002094215A3 (en) 2003-05-01
CA2428785C (en) 2011-04-26
JP2004520443A (ja) 2004-07-08
EP1341521B1 (en) 2009-01-07
EP1341521A2 (en) 2003-09-10
WO2002094215A2 (en) 2002-11-28
JP2010111685A (ja) 2010-05-20
ATE419834T1 (de) 2009-01-15
CA2428785A1 (en) 2002-11-28
JP4541647B2 (ja) 2010-09-08
DE60137362D1 (de) 2009-02-26

Similar Documents

Publication Publication Date Title
WO2002094215A3 (en) Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers
AU2003210517A1 (en) Drug nanoparticles with lysozyme surface stabiliser
WO2005044234A3 (en) Nanoparticulate compositions having a peptide as a surface stabilizer
WO2001062737A3 (en) Amino pyrazole derivatives useful for the treatment of obesity and other disorders
BG104877A (en) N-substituted anminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
CA2416109A1 (en) Solid dose nanoparticulate compositions
CA2339991A1 (en) Microemulsions as solid dosage forms for oral administration
WO2001022791A8 (en) Controlled release compositions comprising nimesulide
SI1802650T1 (sl) Eter in tioeter substituirani ciklosporinski derivati za zdravljenje in preventivo pred infekcijami s hepatitisom c
MY125921A (en) Compositions containing organic compounds
AU2274201A (en) Compounds and compositions for delivering active agents
IL187813A0 (en) Pharmaceutical compositions of a neuroactive steroid and uses thereof
WO2007048219A3 (en) Sustained drug release composition
WO2002007767A3 (en) Pharmaceutical suspension compositions lacking a polymeric suspending agent
EP2269608A3 (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
BR0209020A (pt) Composição farmacêutica de polialilamina
WO2007075972A3 (en) Chlorite formulations, and methods of preparation and use thereof
WO2007050181A3 (en) Metal coordinated compositions
BR0311327A (pt) Composição farmacêutica contendo oxcarbazepina com liberação sustentada de um ingrediente ativo
CA2378834A1 (en) Pyrazinones, compositions containing such compounds
WO2003031467A3 (en) Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
WO2007064620A3 (en) Compositions comprising a combination of ccr5 and cxcr4 antagonists
MXPA03004111A (es) Composiciones de n-(1 -metiletilaminocarbonil)-4 -(3-metilfenilamino) -3-piridil-sulfonamida y oligosacaridos ciclicos con una mayor liberacion.
MY157852A (en) A platform for transdermal formulations (ptf)
AU2002310920A1 (en) Pharmaceutical compositions comprising ascomycin

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase